Building Bone while Making Milk | NEJM
In their study of a mouse model of bone loss during lactation, Babey et al. identified a hormone, secreted by brain cells, that enhances bone mass and strength.
Related Articles
Five reasons to attend Sleep and Breathing 2025
As the largest pan-European meeting of its kind, the Sleep and Breathing Conference is a not-to-be-missed event for respiratory professionals specialising in sleep respiratory medicine…
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Vanzacaftor–tezacaftor–deutivacaftor was safe and well tolerated and maintained FEV1 % predicted from elexacaftor–tezacaftor–ivacaftor baseline with further improved CFTR function. Improvements in CFTR function compared with…
When Diversity Goals Meet Multiregional Trials | NEJM
To achieve goals focused on diversity in clinical research, trials may need to enroll large numbers of U.S. participants. But diversity initiatives and multiregional strategies…
Asundexian versus Apixaban in Patients with Atrial Fibrillation | NEJM
Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor…
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive…
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy | NEJM
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly i…
Asundexian versus Apixaban in Patients with Atrial Fibrillation | NEJM
Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor…
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma | NEJM
Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients…
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | NEJM
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after…
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer | NEJM
Outcomes in patients with hormone receptor–positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients…